Aradigm Corporation (NASDAQ:ARDM) Files An 8-K Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a RegistrantItem 2.03
On June13, 2018, Aradigm Corporation (the “Company”) completed the third closing under the senior note purchase agreement (the “Purchase Agreement”), dated as of April13, 2018, between the Company and the lenders set forth on Schedule A thereto (the “Lenders”). As previously announced, the Company completed the first closing under the Purchase Agreement on April13, 2018, at which time the Company issued and sold approximately $2million aggregate principal amount of 9.0% Senior Promissory Notes due May1, 2021, to the Lenders. The second closing under the Purchase Agreement occurred on May14, 2018, at which time the Company issued and sold a 9.0% Senior Promissory Note due May1, 2021, to one of the Lenders in the aggregate principal amount of approximately $1million. At the third closing under the Purchase Agreement on June13, 2018, the Company issued and sold an additional 9.0% Senior Promissory Note due May1, 2021 (the “Note”), to one of the Lenders in the aggregate principal amount of approximately $1million.
Unless the Company elects otherwise, accrued interest payable on the Note will be capitalized on each applicable interest payment date by adding such accrued interest as of such date to the principal balance of the Note, at which time such interest will be deemed to have been paid.
The Note bears interest at a fixed rate of 9.0% per annum, payable semiannually in arrears on May1 and November1 of each year, beginning on November1, 2018. The Note is the Company’s senior unsecured obligation and ranks (i)senior in right of payment to any of the Company’s indebtedness that is expressly subordinated in right of payment to the Note, (ii)equal in right of payment to any of the Company’s indebtedness that is not so subordinated, including the Company’s 9.0% Convertible Senior Notes due 2021, issued to that certain Indenture, dated as of April25, 2016, between the Company and U.S. Bank National Association, as trustee, as amended, (iii)effectively junior in right of payment to any of the Company’s secured indebtedness to the extent of the value of the assets securing such indebtedness, and (iv)structurally junior to all indebtedness and other liabilities (including trade payables) of the Company’s subsidiaries.
The Company may, at its option, redeem for cash all or any portion of the outstanding Note (on a pro rata basis with any other outstanding 9.0% Senior Promissory Notes due May1, 2021) at any time in whole and, from time to time, in part. There is no sinking fund provided for the Note. The redemption price for the Note on any redemption date will equal 50% of the aggregate principal amount being redeemed plus accrued and unpaid interest to, but excluding, such redemption date.
The events of default under the terms of the Note, any of which may result in the acceleration of the maturity of the Note, include:
(i) the Company’s default in any payment of interest on the Note when due and payable and the default continues for a period of thirty calendar days;
(ii) the Company’s default in the payment of principal of the Note, including capitalized interest, when due and payable at its stated maturity, upon redemption, upon declaration of acceleration or otherwise;
(iii) the Company’s failure to comply with its obligations under the covenant in the Note relating to the consolidation or merger of the Company or the sale of its assets;
(iv) the Company’s failure for sixty days, after written notice from the holder of the Note is received, to comply with any of the Company’s other agreements contained in the Note;
(v) default by the Company or any of its significant subsidiaries with respect to any mortgage, agreement or other instrument under which there may be outstanding, or by which there may be secured or evidenced, any indebtedness for money borrowed in excess of $500,000 (or its foreign currency equivalent) in the aggregate of the Company and/or any such significant subsidiary, whether such indebtedness existed at the time of issuance or where thereafter created, (i)resulting in such indebtedness becoming or being declared due and payable or (ii)constituting a failure to pay the principal or interest of any such indebtedness when due and payable at its stated maturity, upon declaration of acceleration or otherwise if such default is not cured or waived, or such acceleration is not rescinded within thirty calendar days;
(vi) a final judgment for the payment of $500,000 (or its foreign currency equivalent) or more (excluding any amounts covered by insurance) in the aggregate rendered against the Company or any of the Company’s significant subsidiaries, which judgment is not paid, discharged or stayed within sixty calendar days after (i)the date on which the right to appeal thereof has expired, if no such appeal has commenced or (ii)the date on which all rights to appeal have been extinguished; and
(vii) certain events of bankruptcy, insolvency or reorganization of the Company or any of its significant subsidiaries.
The above descriptions of the Purchase Agreement and the Note do not purport to be complete and are qualified in their entirety by reference to the Form of Note and the Purchase Agreement, which are filed as Exhibit 1.1 and Exhibit 4.1 to this report and are incorporated herein by reference.
|Item 2.03||Financial Statements and Exhibits.|
|(1)||Incorporated by reference to Exhibit 1.1 to the Company’s Form 8-K (No. 001-36480) filed on April18, 2018.|
|(2)||Incorporated by reference to Exhibit 4.1 to the Company’s Form 8-K (No. 001-36480) filed on April18, 2018.|
About Aradigm Corporation (NASDAQ:ARDM)
Aradigm Corporation is a pharmaceutical company focused on the development and commercialization of products for the treatment and prevention of severe respiratory diseases. The Company’s lead product candidate is Pulmaquin inhaled ciprofloxacin, which is in Phase III clinical trials. It offers AERx pulmonary drug delivery platform and other technologies. Its partnered programs under development include Inhaled Ciprofloxacin. It is also engaged in developing Smoking Cessation Therapy (ARD-1600 Inhaled Nicotine). Its lead development candidates are its formulations of the potent antibiotic ciprofloxacin (Pulmaquin (ARD-3150) and Lipoquin (ARD-3100)) that are delivered by inhalation for the management of infections associated with the severe respiratory diseases, such as cystic fibrosis (CF) and non-cystic fibrosis bronchiectasis (BE). Pulmaquin uses slow release liposomal formulation (Lipoquin) mixed with a small amount of ciprofloxacin dissolved in an aqueous medium.